Ingevity (NYSE:NGVT) Announces Earnings Results

Key Points

• Ingevity reported quarterly EPS of $1.15, beating the consensus of $0.84, with revenue up 4.1% year-over-year and updated FY 2026 guidance to $4.70–$5.20 EPS.
• Shares climbed to $77.85 on Wednesday with above-average volume; the company has a market cap of $2.75 billion and a reported price-to-earnings ratio of -16.74.
• Analysts are mixed (consensus rating: Hold with an $80 average price target) while institutional investors have been adding shares heavily — institutional ownership is 91.59%.

Ingevity (NYSE:NGVT - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.84 by $0.31, Zacks reports. Ingevity had a negative net margin of 13.51% and a positive return on equity of 126.25%. During the same quarter in the prior year, the company earned $1.01 earnings per share. The firm's revenue was up 4.1% on a year-over-year basis. Ingevity updated its FY 2026 guidance to 4.700-5.200 EPS.

Ingevity Stock Performance

Shares of NYSE NGVT traded up $0.75 during midday trading on Wednesday, reaching $77.85. 282,275 shares of the stock were exchanged, compared to its average volume of 218,940. The company has a quick ratio of 0.79, a current ratio of 1.33 and a debt-to-equity ratio of 39.10. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -16.74 and a beta of 1.24. The firm has a 50-day simple moving average of $71.14 and a two-hundred day simple moving average of $64.01. Ingevity has a twelve month low of $36.47 and a twelve month high of $79.29.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NGVT. Wells Fargo & Company boosted their price target on Ingevity from $65.00 to $75.00 and gave the company an "equal weight" rating in a research note on Friday, February 27th. BMO Capital Markets reiterated an "outperform" rating and issued a $83.00 target price on shares of Ingevity in a research report on Monday, March 2nd. Wall Street Zen lowered shares of Ingevity from a "buy" rating to a "hold" rating in a research report on Saturday, April 4th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $82.00 price objective on shares of Ingevity in a report on Thursday, February 26th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Ingevity in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $80.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Ingevity by 311.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company's stock valued at $23,769,000 after acquiring an additional 454,579 shares during the period. Simcoe Capital Management LLC raised its holdings in Ingevity by 188.8% in the 2nd quarter. Simcoe Capital Management LLC now owns 624,935 shares of the company's stock worth $26,928,000 after purchasing an additional 408,508 shares during the period. Boston Partners boosted its position in Ingevity by 141.6% during the fourth quarter. Boston Partners now owns 620,360 shares of the company's stock worth $36,719,000 after purchasing an additional 363,584 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Ingevity by 137.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 424,038 shares of the company's stock worth $25,095,000 after purchasing an additional 245,620 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in Ingevity by 217.4% in the third quarter. Marshall Wace LLP now owns 228,201 shares of the company's stock valued at $12,594,000 after purchasing an additional 156,301 shares during the period. Hedge funds and other institutional investors own 91.59% of the company's stock.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.